The Company has 8,396,600 warrants outstanding from prior financings EMCs Position in the Company Emerging Markets Consulting participated directly in this financing by investing: CAD $671,356 Purchasing: 1,342,712 shares at CAD $0.50 per share, representing approximately 33.6% of the CAD $2,000,000 offering (Note: $671,356 of a $2,000,000 round is 33.6%.) In addition, we separately acquired: 1,000,000 additional shares through a private transaction EMCs total holding of 2,342,712 shares represents approximately 4.47% of the 52,431,207 common shares outstanding
[6] These analyses are useful, but they are the weakest tier for a two-drug verdict: indirect comparisons inherit every difference between the underlying trials and cannot substitute for a randomised head-to-head
While human research remains limited, the consistency of animal findings supports the mechanism
BPC-157 (10mg) A synthetic 15-amino-acid peptide fragment studied in research involving signaling pathways related to tissue response, angiogenic activity, and cellular communication
